TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25096860

Group type: EXPERIMENTAL
Intervention: PRISm subjects
Number of subjects: 10192

Group type: EXPERIMENTAL
Intervention: GWAS testing
Number of subjects: 10192

Group type: EXPERIMENTAL
Intervention: K-means clustering
Number of subjects: 10192
Study: 25097199

Group type: EXPERIMENTAL
Intervention: Transendocardial CD34(+) cell transplantation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 33
Study: 25098184

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention (text message and voucher component)
Number of subjects: 2550

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention
Number of subjects: 2550
Study: 25098565

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGBP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RYGBP
Number of subjects: 36
Study: 25098701

Group type: EXPERIMENTAL
Intervention: Bevacizumab monotherapy
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Bevacizumab combination therapy
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Bevacizumab (monotherapy and combination)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Prior hypertension
Number of subjects: 210
Study: 25099027

Group type: EXPERIMENTAL
Intervention: TACE/sorafenib combination
Number of subjects: 192
Study: 25100734

Group type: EXPERIMENTAL
Intervention: Exercise (≥30 min, 3 times per week)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Non-exercise (sedentary)
Number of subjects: 274
Study: 25101571

Group type: EXPERIMENTAL
Intervention: Nitinol stent treatment
Number of subjects: 998
Study: 25102193

Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy
Number of subjects: 12
Study: 25102383

Group type: EXPERIMENTAL
Intervention: Cumulative Illness Rating Scale-Geriatric (CIRS-G)
Number of subjects: 76
Study: 25103305

Group type: EXPERIMENTAL
Intervention: Erlotinib treatment
Number of subjects: 23
Study: 25103395

Group type: EXPERIMENTAL
Intervention: DPP T1 (treponemal) assay
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: DPP T2 (non-treponemal) assay
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: DPP T2 assay for specimens with an RPR titre of 1:8 or greater
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: DPP assay in children with dual-positive serology
Number of subjects: 703
Study: 25103848

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 131

Group type: COMPARATOR
Intervention: Laser treatment
Number of subjects: 131
Study: 25103913

Group type: EXPERIMENTAL
Intervention: FDG PET-MRI
Number of subjects: 20

Group type: COMPARATOR
Intervention: FDG PET-CT
Number of subjects: 20
Study: 25104514

Group type: EXPERIMENTAL
Intervention: iSVT
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: iD-DVT
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: iP-DVT
Number of subjects: 1167
Study: 25104797

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pooled group of patients undergoing bariatric surgery
Number of subjects: 22
Study: 25105369

Group type: EXPERIMENTAL
Intervention: Gene therapy with O6BG/TMZ chemotherapy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Historical controls without gene therapy
Number of subjects: 7
Study: 25105742

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs)
Number of subjects: 50
Study: 25105826

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) parameters: LF > 298 ms
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) parameters: LF/HF > 3.1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Correlation between LF and NRS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Correlation between LF/HF and NRS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Correlation between HF and NRS
Number of subjects: 120
Study: 25105850

Group type: EXPERIMENTAL
Intervention: Continuous noninvasive arterial pressure (CNAP) device
Number of subjects: 104
Study: 25106049

Group type: EXPERIMENTAL
Intervention: Physical Activity Acceptance Questionnaire (PAAQ)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Cognitive Acceptance subscale of PAAQ
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: PAAQ (test-retest reliability)
Number of subjects: 418
Study: 25106673

Group type: EXPERIMENTAL
Intervention: Spinal manipulation (SM) - side-lying, high velocity, low amplitude, over a course of 6 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Spinal manipulation (SM)
Number of subjects: 80
Study: 25106676

Group type: EXPERIMENTAL
Intervention: 16 weeks weight loss intervention
Number of subjects: 192
Study: 25107437

Group type: EXPERIMENTAL
Intervention: Endovascular stenting
Number of subjects: 300
Study: 25109929

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25110173

Group type: EXPERIMENTAL
Intervention: Immediate drying and wrapping of the baby
Number of subjects: 22243

Group type: EXPERIMENTAL
Intervention: Delayed bathing practices
Number of subjects: 22243

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care
Number of subjects: 22243

Group type: EXPERIMENTAL
Intervention: General thermal care behaviours
Number of subjects: 22243
Study: 25110632

Group type: EXPERIMENTAL
Intervention: 7.5 μg single dose
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: 15 μg single dose
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: 7.5 μg two doses
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: 15 μg two doses
Number of subjects: 312
Study: 25111234

Group type: EXPERIMENTAL
Intervention: Azithromycin treatment (median duration 4 days, range 2-7 days)
Number of subjects: 18
Study: 25112732

Group type: EXPERIMENTAL
Intervention: LCN2 levels in sera of healthy volunteers subjected to bed rest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OBs-Lcn2 (osteoblasts transfected with LCN2-expression-vector)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OBs-Lcn2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioned media from OBs-Lcn2 cultures or coculture with OBs-Lcn2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombinant LCN2 treatment
Number of subjects: 0
Study: 25112957

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (IMV)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Viral load monitoring
Number of subjects: 5
Study: 25113510

Group type: EXPERIMENTAL
Intervention: Discovery Link AFinder
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 472

Group type: COMPARATOR
Intervention: Standard in-hospital monitoring
Number of subjects: 472
Study: 25113573

Group type: EXPERIMENTAL
Intervention: Self-paced stair-climbing test measuring mechanical efficiency (MEnet)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Predicted MEnet for T2 and T1
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Stair-climbing test
Number of subjects: 43
Study: 25113756

Group type: EXPERIMENTAL
Intervention: LCL161 (1,800 mg, oral, once weekly, tablet formulation)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: LCL161 (tablet formulation)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: LCL161 (1,800 mg)
Number of subjects: 53
Study: 25113840

Group type: EXPERIMENTAL
Intervention: Vessel-calibre MRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional assessments of tumour volume
Number of subjects: 0
Study: 25114140

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (LPV/r)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nevirapine
Number of subjects: 0
Study: 25114584

Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg/day)
Number of subjects: 103
Study: 25114718

Group type: EXPERIMENTAL
Intervention: anti-HER2 agents
Number of subjects: 15
Study: 25114916

Group type: EXPERIMENTAL
Intervention: Children with ASD during routine dental cleanings
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Physiological measures of distress in children with ASD
Number of subjects: 44

Group type: COMPARATOR
Intervention: Behavioral distress in the typical group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Behavioral distress in the ASD group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Physiological distress in the typical group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Physiological distress in the ASD group
Number of subjects: 44
Study: 25115686

Group type: EXPERIMENTAL
Intervention: Resveratrol (1 gm daily for 12 weeks)
Number of subjects: 40
Study: 25115882

Group type: EXPERIMENTAL
Intervention: Extended follow-up studies
Number of subjects: 0
Study: 25115992

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 60
Study: 25116755

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, GM-CSF-secreting breast tumor vaccine, and trastuzumab
Number of subjects: 20
Study: 25116908

Group type: EXPERIMENTAL
Intervention: Tai chi meditation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25117135

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25117475

Group type: EXPERIMENTAL
Intervention: Cabazitaxel/cisplatin (15/75 mg/m²)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cabazitaxel/cisplatin (20/75 mg/m²)
Number of subjects: 25
Study: 25117615

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 250 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 500 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1000 mg (1 h premeal)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1000 mg (2 h postmeal)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA)
Number of subjects: 27
Study: 25119513

Group type: EXPERIMENTAL
Intervention: Relaxation module
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Exercise module
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cognitive Coping module
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Patient-therapist working alliance and patient expectations of treatment benefit
Number of subjects: 56
Study: 25119856

Group type: EXPERIMENTAL
Intervention: Gene expression score (GES) for obstructive CAD in the PREDICT cohort
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Gene expression score (GES) for obstructive CAD in the original validation cohort
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Gene expression score (GES) for obstructive CAD in non-Caucasian patients
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Gene expression score (GES) for obstructive CAD in Caucasian patients
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Re-testing of stored samples from the original validation cohort after 5 years
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Gene expression score (GES) for obstructive CAD in the COMPASS study
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Changes in cardiovascular medications
Number of subjects: 1675
Study: 25122609

Group type: EXPERIMENTAL
Intervention: ABC294640 (a SK2 specific inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABC294640
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABC294640 + ABT-737 (a Bcl-2 inhibitor)
Number of subjects: 0
Study: 25122629

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous needle electrolysis (PNE) with eccentric exercise (EccEx) and stretching, 1 session per week for 4-6 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous needle electrolysis (PNE) with eccentric exercise (EccEx) and stretching
Number of subjects: 36
Study: 25122650

Group type: COMPARATOR
Intervention: Pica group (n = 72)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Non-pica group (n = 86)
Number of subjects: 158
Study: 25122663

Group type: EXPERIMENTAL
Intervention: Plasma PL-saturated fatty acid
Number of subjects: 2448

Group type: EXPERIMENTAL
Intervention: Endogenously synthesized PL ω6 fatty acids (20:3n-6)
Number of subjects: 2448

Group type: EXPERIMENTAL
Intervention: Endogenously synthesized PL ω6 fatty acids (22:5n-6)
Number of subjects: 2448

Group type: EXPERIMENTAL
Intervention: Δ6-desaturase
Number of subjects: 2448

Group type: EXPERIMENTAL
Intervention: PL-ω3 fatty acids (20:5n-3)
Number of subjects: 2448

Group type: EXPERIMENTAL
Intervention: PL-ω3 fatty acids (22:5n-3)
Number of subjects: 2448

Group type: EXPERIMENTAL
Intervention: PL-ω3 fatty acids (22:6n-3)
Number of subjects: 2448

Group type: EXPERIMENTAL
Intervention: 18:1n-7
Number of subjects: 2448

Group type: EXPERIMENTAL
Intervention: Δ5-desaturase
Number of subjects: 2448
Study: 25123120

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Number of subjects: 55
Study: 25123851

Group type: EXPERIMENTAL
Intervention: Testosterone 2% solution (Axiron®), 60-mg daily morning dose applied to axillae (30 mg/axilla)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Single testosterone measurements
Number of subjects: 155
Study: 25124284

Group type: EXPERIMENTAL
Intervention: Asymptomatic Intracranial Atherosclerosis (ICAD) detected via MRI
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Smokeless tobacco use
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Western diet
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High socioeconomic status
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 200

Group type: COMPARATOR
Intervention: Age, gender, diabetes, hypertension, depression, and physical activity
Number of subjects: 200
Study: 25125207

Group type: EXPERIMENTAL
Intervention: Harmonic Ace
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Thunderbeat
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Enseal
Number of subjects: 14
Study: 25125294

Group type: EXPERIMENTAL
Intervention: Irrigated contact force (CF)-sensing catheter
Number of subjects: 172
Study: 25125727

Group type: EXPERIMENTAL
Intervention: Denervated myocardium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Denervated myocardium > 37.6% of left ventricle (LV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LV end-diastolic volume > 98 mL/m(2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creatinine level > 1.49 mg/dL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No angiotensin-inhibition therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absence of all four factors (denervated myocardium, LV end-diastolic volume, creatinine level, angiotensin-inhibition therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two or more factors (denervated myocardium, LV end-diastolic volume, creatinine level, angiotensin-inhibition therapy)
Number of subjects: 0
Study: 25125973

Group type: EXPERIMENTAL
Intervention: Prefilled pen (Metex(®) PEN/Metoject(®) PEN)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Self-Injection Assessment Questionnaire (SIAQ)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Prefilled syringe (Metex(®)/Metoject(®))
Number of subjects: 120
Study: 25126038

Group type: EXPERIMENTAL
Intervention: Arousal index
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: RCREC (respiratory cycle-related EEG changes)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Neurobehavioral measures
Number of subjects: 133
Study: 25126421

Group type: EXPERIMENTAL
Intervention: 6MHP vaccine
Number of subjects: 23
Study: 25126443

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of autologous bone marrow mononuclear cells (BMMNCs)
Number of subjects: 24
Study: 25126880

Group type: EXPERIMENTAL
Intervention: Abnormal capillary microvascular flow index (< 2.6)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Tachycardia (heart rate > 90 beats/min)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Vasopressor use
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Lactate level more than 1.5 mEq/L
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Abnormal microvascular flow index in patients with tachycardia
Number of subjects: 501
Study: 25127916

Group type: EXPERIMENTAL
Intervention: Steroid regimen with median dosing of 55 mg/m2/day, median cumulative dose of 3,440 mg/m2 for the first episode, median duration of 21 weeks.
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Symptomatic treatment including albumin infusions, diuretics, and acetyl salicylic acid.
Number of subjects: 231
Study: 25127973

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hsTnT)
Number of subjects: 2046
Study: 25128349

Group type: EXPERIMENTAL
Intervention: NaF PET/CT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Number of subjects: 0

Group type: COMPARATOR
Intervention: NaF and FDG
Number of subjects: 0
Study: 25129345

Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m² every 3 weeks for four cycles
Number of subjects: 107
Study: 25130920

Group type: EXPERIMENTAL
Intervention: Lixisenatide plus basal insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal insulin alone
Number of subjects: 0
Study: 25130947

Group type: EXPERIMENTAL
Intervention: 88 μg·kg(-1) of epinephrine (1:10,000) injected into the caudal epidural space
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group not mentioned
Number of subjects: 1
Study: 25131866

Group type: EXPERIMENTAL
Intervention: Cabazitaxel with prednisone/prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitoxantrone with prednisone/prednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitoxantrone
Number of subjects: 0
Study: 25132507

Group type: EXPERIMENTAL
Intervention: 10 μg vaccine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 20 μg vaccine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 40 μg vaccine
Number of subjects: 25
Study: 25133198

Group type: EXPERIMENTAL
Intervention: Rifaximin 1.2 g/day for 15 days/month for 2 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25133431

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg subcutaneously for 84 days
Number of subjects: 10
Study: 25133535

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 9
Study: 25134640

Group type: EXPERIMENTAL
Intervention: Genetic variants associated with total lung capacity (TLC) in COPD, specifically SNP rs114929486 on chromosome 5p15.2.
Number of subjects: 4543
Study: 25135035

Group type: EXPERIMENTAL
Intervention: Pregabalin (100, 150, 300, or 600 mg/day)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 152
Study: 25135178

Group type: EXPERIMENTAL
Intervention: National Cholesterol Education Program step 1 diet plus pravastatin (n=3866)
Number of subjects: 7832

Group type: COMPARATOR
Intervention: National Cholesterol Education Program step 1 diet alone (n=3966)
Number of subjects: 7832

Group type: EXPERIMENTAL
Intervention: Both diet-alone and diet-plus-pravastatin groups
Number of subjects: 7832
Study: 25135232

Group type: EXPERIMENTAL
Intervention: Cold crystalloid renal perfusion
Number of subjects: 1267

Group type: EXPERIMENTAL
Intervention: Left heart bypass
Number of subjects: 1267

Group type: EXPERIMENTAL
Intervention: Isothermic visceral perfusion
Number of subjects: 1267

Group type: EXPERIMENTAL
Intervention: Patient-specific surgical adjuncts (endarterectomy, open stent placement)
Number of subjects: 1267

Group type: EXPERIMENTAL
Intervention: Overall operative mortality
Number of subjects: 1267

Group type: EXPERIMENTAL
Intervention: Thirty-day survival
Number of subjects: 1267

Group type: EXPERIMENTAL
Intervention: Bowel ischemia
Number of subjects: 1267

Group type: EXPERIMENTAL
Intervention: Extent II and III TAAA repairs
Number of subjects: 1267
Study: 25135443

Group type: EXPERIMENTAL
Intervention: Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSE™)
Number of subjects: 69
Study: 25135992

Group type: EXPERIMENTAL
Intervention: R2CHOP (lenalidomide 25 mg orally per day on days 1-10 combined with standard-dose R-CHOP every 21 days for six cycles)
Number of subjects: 64

Group type: COMPARATOR
Intervention: R-CHOP (control group from Lymphoma Database)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: R2CHOP
Number of subjects: 64
Study: 25135998

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin administered sequentially with CHOP
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin 1.8 mg/kg plus CHP (BV+CHP)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin administered sequentially with CHOP or in combination with CHP
Number of subjects: 26
Study: 25136024

Group type: COMPARATOR
Intervention: Tedizolid phosphate 200 mg (single oral dose for hepatic impairment, intravenous for renal impairment); hemodialysis subjects received two doses (separated by 7 days) before and after dialysis.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tedizolid phosphate 200 mg; administered to subjects with moderate or severe hepatic impairment.
Number of subjects: 0
Study: 25136079

Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnostic technologies (optical coherence tomography)
Number of subjects: 0
Study: 25136536

Group type: EXPERIMENTAL
Intervention: 3 g Korean white ginseng (KWG)
Number of subjects: 25
Study: 25136689

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injections (5 weekly injections)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 50
Study: 25136951

Group type: EXPERIMENTAL
Intervention: Transpulmonary thermodilution using a port-a-catheter (CIport)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Transpulmonary thermodilution using central venous access (CIcvc)
Number of subjects: 27
Study: 25137424

Group type: EXPERIMENTAL
Intervention: Endometriosis lesions
Number of subjects: 76

Group type: COMPARATOR
Intervention: Endometrial tissue progesterone (P4) concentrations
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Endometriosis lesions with contraceptive medication
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ovarian lesions
Number of subjects: 76